Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

(2018) Anne-Sophie Michallet et al.   HAEMATOLOGICA

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

(2018) Anne-Sophie Michallet et al.   HAEMATOLOGICA

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

(2016) Barbara Eichhorst et al.   LANCET ONCOLOGY

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) B. Eichhorst et al.   ANNALS OF ONCOLOGY

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

(2015) V Goede et al.   LEUKEMIA

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms

(2014) Wolfgang Knauf et al.   HEMATOLOGICAL ONCOLOGY

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

(2014) Peter Hillmen et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials

(2013) Morag Meriel Griffin et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

(2012) M. Ghielmini et al.   ANNALS OF ONCOLOGY

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2012) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2011) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic lymphocytic leukemia: planning for an aging population

(2010) John G Gribben   Expert Review of Anticancer Therapy

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Disease burden of chronic lymphocytic leukaemia within the European Union

(2008) Louise Watson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

(2008) Paul Thurmes et al.   LEUKEMIA & LYMPHOMA